| rs17507185 |
chr5 |
31802554 |
0.00054 |
G |
A |
Alzheimer's disease |
PDZD2 |
intron |
24755620
|
| rs7731219 |
chr5 |
31804573 |
0.000988 |
A |
G |
Alcohol dependence |
PDZD2 |
intron |
21314694
|
| rs13182171 |
chr5 |
31812179 |
0.000000802 |
A |
C |
Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels) |
PDZD2 |
intron |
24528284
|
| rs34301697 |
chr5 |
31813639 |
0.000000842 |
A |
G |
Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels) |
PDZD2 |
intron |
24528284
|
| rs4867084 |
chr5 |
31818948 |
0.00004 |
G |
A |
Asthma (aspirin-intolerant) |
PDZD2 |
intron |
21072201
|
| rs4867084 |
chr5 |
31818948 |
0.000651 |
G |
A |
Alcohol dependence |
PDZD2 |
intron |
21314694
|
| rs10042146 |
chr5 |
31833816 |
0.0000921 |
A |
G |
Orofacial clefts |
PDZD2 |
intron |
22419666
|
| rs6874198 |
chr5 |
31838491 |
0.0000281 |
A |
G |
Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs) |
PDZD2 |
intron |
23648065
|
| rs7710487 |
chr5 |
31853188 |
0.0000578 |
T |
G |
Cognitive test performance |
PDZD2 |
intron |
20125193
|
| rs6882892 |
chr5 |
31872998 |
0.0000945 |
T |
G |
Panic disorder |
PDZD2 |
intron |
23149450
|
| rs6882892 |
chr5 |
31872998 |
0.0000945 |
T |
G |
Serum tamsulosin hydrochloride concentration |
PDZD2 |
intron |
23151678
|
| rs12519922 |
chr5 |
31891018 |
0.00000791 |
G |
C |
Serum metabolites |
PDZD2 |
intron |
19043545
|
| rs11957407 |
chr5 |
31917242 |
0.000003 |
G |
A |
Bipolar disorder (body mass index interaction) |
PDZD2 |
intron |
24322204
|
| rs35888615 |
chr5 |
31924212 |
0.00078 |
G |
A |
Urinary metabolites |
PDZD2 |
intron |
21572414
|
| rs9292449 |
chr5 |
31925190 |
0.000403 |
A |
C |
Type 2 diabetes |
PDZD2 |
intron |
17463246
|
| rs6450876 |
chr5 |
31925423 |
0.000539 |
A |
G |
Type 2 diabetes |
PDZD2 |
intron |
17463246
|
| rs7719829 |
chr5 |
31927317 |
0.000004 |
A |
G |
Obesity-related traits |
PDZD2 |
intron |
23251661
|
| rs7719829 |
chr5 |
31927317 |
0.000462 |
A |
G |
Lung function (forced expiratory volume in 1 second) |
PDZD2 |
intron |
24023788
|
| rs4867405 |
chr5 |
31944975 |
0.00002 |
G |
A |
Response to taxane treatment (placlitaxel) |
PDZD2 |
intron |
23006423
|
| rs7724279 |
chr5 |
31957885 |
0.000304 |
A |
G |
Response to taxane treatment (placlitaxel) |
PDZD2 |
intron |
23006423
|
| rs7726919 |
chr5 |
31967192 |
0.000947 |
T |
G |
Response to taxane treatment (placlitaxel) |
PDZD2 |
intron |
23006423
|
| rs12110008 |
chr5 |
31969830 |
0.000332 |
C |
T |
Alzheimer's disease (late onset) |
PDZD2 |
intron |
21379329
|
| rs12186888 |
chr5 |
31974510 |
0.000954 |
C |
T |
Amyotrophic Lateral Sclerosis |
PDZD2 |
intron |
17362836
|
| rs12186888 |
chr5 |
31974510 |
0.000086 |
C |
T |
Monocyte counts |
PDZD2 |
intron |
pha003089
|
| rs6450883 |
chr5 |
31980113 |
0.000926 |
G |
T |
Methotrexate clearance (acute lymphoblastic leukemia) |
PDZD2 |
intron |
23233662
|
| rs6450884 |
chr5 |
31980161 |
0.000918 |
C |
T |
Methotrexate clearance (acute lymphoblastic leukemia) |
PDZD2 |
intron |
23233662
|
| rs13179903 |
chr5 |
31982574 |
0.00072 |
G |
A |
Urinary metabolites |
PDZD2 |
intron |
21572414
|
| rs6878827 |
chr5 |
31988389 |
0.00000489 |
T |
G |
Type 2 diabetes |
PDZD2 |
intron |
17463246
|
| rs6861526 |
chr5 |
31992572 |
0.000297 |
T |
C |
Multiple complex diseases |
PDZD2 |
intron |
17554300
|
| rs6861526 |
chr5 |
31992572 |
0.000151 |
T |
C |
Multiple sclerosis |
PDZD2 |
intron |
17660530
|
| rs10054504 |
chr5 |
32000483 |
0.000004 |
T |
C |
Urinary metabolites |
PDZD2 |
intron |
21572414
|
| rs10054504 |
chr5 |
32000483 |
0.000111 |
T |
C |
White matter integrity |
PDZD2 |
intron |
22425255
|
| rs10054504 |
chr5 |
32000483 |
0.0000008 |
T |
C |
Renal cell carcinoma |
PDZD2 |
intron |
23184150
|
| rs4867100 |
chr5 |
32007713 |
0.000007 |
C |
T |
Urinary metabolites |
PDZD2 |
intron |
21572414
|
| rs1532269 |
chr5 |
32018841 |
0.000711 |
C |
G |
Response to TNF antagonist treatment |
PDZD2 |
intron |
21061259
|
| rs10039073 |
chr5 |
32042760 |
0.0000546 |
G |
A |
Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) |
PDZD2 |
intron |
24023788
|
| rs323827 |
chr5 |
32044573 |
0.0000864 |
G |
A |
Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) |
PDZD2 |
intron |
24023788
|
| rs422224 |
chr5 |
32049293 |
0.000139 |
G |
C |
Multiple complex diseases |
PDZD2 |
intron |
17554300
|
| rs17433352 |
chr5 |
32049787 |
0.00076 |
C |
T |
Multiple complex diseases |
PDZD2 |
intron |
17554300
|
| rs328620 |
chr5 |
32050651 |
0.000202 |
C |
G |
Obesity (extreme) |
PDZD2 |
intron |
21935397
|
| rs161535 |
chr5 |
32053321 |
0.0000372 |
C |
T |
Body mass index |
PDZD2 |
intron |
17255346
|
| rs161533 |
chr5 |
32056026 |
0.0000833 |
C |
T |
Body mass index |
PDZD2 |
intron |
17255346
|
| rs157500 |
chr5 |
32060695 |
0.0000365 |
C |
T |
White matter integrity |
PDZD2 |
intron |
22425255
|
| rs11955676 |
chr5 |
32061570 |
0.000036 |
C |
T |
Information processing speed |
PDZD2 |
intron |
21130836
|
| rs12110295 |
chr5 |
32062984 |
0.000478 |
T |
G |
Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) |
PDZD2 |
intron |
20877124
|
| rs12110295 |
chr5 |
32062984 |
0.0000542 |
T |
G |
White matter integrity |
PDZD2 |
intron |
22425255
|
| rs12054657 |
chr5 |
32067373 |
0.000381 |
G |
A |
Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) |
PDZD2 |
intron |
20877124
|
| rs10065850 |
chr5 |
32067398 |
0.000674 |
A |
G |
Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) |
PDZD2 |
intron |
20877124
|
| rs283129 |
chr5 |
32067671 |
0.0000183 |
T |
C |
Glucose levels |
PDZD2 |
intron |
pha003061
|
| rs6862076 |
chr5 |
32069910 |
0.000401 |
T |
C |
Insulin resistance |
PDZD2 |
intron |
21901158
|
| rs3797064 |
chr5 |
32072213 |
0.000898 |
A |
C |
Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) |
PDZD2 |
intron |
20877124
|
| rs4867417 |
chr5 |
32076782 |
0.000786 |
A |
G |
Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) |
PDZD2 |
intron |
20877124
|
| rs4867417 |
chr5 |
32076782 |
0.0000893 |
A |
G |
White matter integrity |
PDZD2 |
intron |
22425255
|
| rs157494 |
chr5 |
32087228 |
0.0001 |
C |
T |
Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes |
PDZD2 |
intron |
22628534
|
| rs3101878 |
chr5 |
32087326 |
0.00042 |
C |
A |
Urinary metabolites |
PDZD2 |
missense |
21572414
|
| rs3135427 |
chr5 |
32087430 |
0.00019 |
G |
A |
Urinary metabolites |
PDZD2 |
cds-synon |
21572414
|
| rs3101873 |
chr5 |
32088500 |
0.00014 |
C |
T |
Urinary metabolites |
PDZD2 |
missense |
21572414
|